The Trump administration has indicated it will allow up to five states to test new ways of managing their Medicaid prescription drug programs, and recent proposals by Massachusetts and Arizona to use some of the cost-control tools available in the commercial market seem tailor-made for this plan. But there are many more ways that Medicaid programs could tackle drug costs than are outlined in the administration’s 28-page report, says Trish Riley in a new Health Affairs blog post.